By regulating the expression of transcription factor c-myc and Wnt5a, BRD4 is ascribed as a key determinant in acute myeloid leukemia (AML), multiple myeloma, Burkitt’s lymphoma, colon cancer, and inflammatory diseases37,38. This evidence concerns the gene MYC and plasma cell myeloma.